Mariana Bastos-Oreiro
Hospital General Universitario Gregorio Marañon
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mariana Bastos-Oreiro as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07254754 · Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · recruiting · DIFFUSE LARGE B-CELL LYMPHOMA · principal investigator
- Ph2NCT07126236 · Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · recruiting · Large B Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:00 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.Leuk Lymphoma · 202222 citationsRCR 1.3
- Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.Lancet Haematol · 202417 citationsRCR 1.9
- Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.Blood Adv · 202516 citationsRCR 3.3
- Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.Blood Adv · 20258 citationsRCR 1.7